Develops engineered regulatory T cells (Tregs) to restore immune tolerance in patients with severe autoimmune, inflammatory, or transplant-related diseases. By rebalancing the immune system, these therapies aim to prevent tissue damage, chronic inflammation, and graft rejection, offering a potential long-term solution for conditions lacking effective treatments.
Funding
$264.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FFounders
Product
Problem
The immune system's delicate balance between self-tolerance and response to external threats can be disrupted, leading to autoimmunity, chronic inflammation, and graft rejection in organ transplantation. Current treatments often fail to provide long-lasting control for patients with severe immune diseases.
Solution
Quell Therapeutics engineers regulatory T cells (Tregs) to restore immune tolerance in patients with severe autoimmune, inflammatory, or transplant-related diseases. By harnessing the potential of Tregs, Quell aims to re-establish immune balance, offering long-lasting control and preventing tissue damage, chronic inflammation, and graft rejection. The approach involves engineering a patient's own Tregs to develop treatments with the potential to transform and save lives.
Target Audience
The primary target audience includes patients suffering from severe autoimmune, inflammatory, or transplant-related diseases, as well as healthcare providers specializing in these conditions.
Features
- Engineered Treg cell therapies for autoimmune and inflammatory diseases
- Modulation of the immune system to restore balance and prevent autoreactivity
- Development of treatments to prevent tissue damage and chronic inflammation
- Potential for long-lasting control of severe immune diseases